Abstract
Ribavirin is a broad-spectrum antiviral drug and is used to treat diseases caused by many viral infections. In this study, high-pressure liquid chromatographic and UV-Vis spectrophotometric methods were developed, validated and statistically compared to determine the amount of ribavirin in pharmaceutical preparations. HPLC analyses were performed by UV detection at 207 nm using a mobile phase consisting of 20mm KH2P04 with a flow rate of 0.8 mL min-1 on a C18 column. Ultrapure water was used as a solvent in spectrophotometric analyses. The UV spectrum of the standard and sample solutions was recorded between 200 and 400 nm and absorbance values were measured at 207 nm. Both methods were validated according to the procedures described in ICH guidelines Q2(R1) for verification of analytical methods. The results showed that spectrophotometric and liquid chromatographic methods were linear, precise, accurate, rugged, and robust with RSD values less than 1.00%, and the recovery percentage was within standard limits (98-102%). Then a statistical comparison of these two analytical methods was performed, and the results showed no significant difference. As a result, the developed analytical methods were determined to be accurate, highly effective, reliable, fast, simple, and could be used for routine quality control analysis of ribavirin in pharmaceutical formulations.
Highlights
As of September 24, 2021, the World Health Organization reported 4.724.876 deaths and 230.418.451 cases of COVID-19 globally [1]
Because of the appropriate molar absorptivity of RBVN in this region, a wavelength of 207 nm was selected for measurements
It was determined that there was a linear connection between the concentration of the standard solution and the response for both methods
Summary
As of September 24, 2021, the World Health Organization reported 4.724.876 deaths and 230.418.451 cases of COVID-19 globally [1]. COVID-19, a novel coronavirus-related pneumonia, has become a public health disaster on a global scale [2]. Ribavirin (RBVN) is a nucleoside analog that has been synthesized. It is an antiviral drug that is active against both DNA and RNA viruses [5]. It was used for antiviral therapy, taking into account its broad-spectrum antiviral activity, during the outbreak of severe acute respiratory syndrome in 2003 and the Middle East respiratory syndrome in 2012 [6,7,8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
